COL-1620 + Gonadotropin-releasing hormone (GnRH) analogue + Follicle-stimulating hormone (FSH) + Human Chorionic Gonadotropin (hCG)
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Luteal Hormone Supplementation in In-vitro Fertilization
Conditions
Luteal Hormone Supplementation in In-vitro Fertilization, Embryo Transfer
Trial Timeline
Jul 1, 2013 → Oct 1, 2014
NCT ID
NCT01863680About COL-1620 + Gonadotropin-releasing hormone (GnRH) analogue + Follicle-stimulating hormone (FSH) + Human Chorionic Gonadotropin (hCG)
COL-1620 + Gonadotropin-releasing hormone (GnRH) analogue + Follicle-stimulating hormone (FSH) + Human Chorionic Gonadotropin (hCG) is a phase 3 stage product being developed by Merck for Luteal Hormone Supplementation in In-vitro Fertilization. The current trial status is completed. This product is registered under clinical trial identifier NCT01863680. Target conditions include Luteal Hormone Supplementation in In-vitro Fertilization, Embryo Transfer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01863680 | Phase 3 | Completed |
Competing Products
1 competing product in Luteal Hormone Supplementation in In-vitro Fertilization
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| progesterone + Progesterone | Merck | Approved | 85 |